<DOC>
	<DOC>NCT01635985</DOC>
	<brief_summary>The purpose of this study is to look at drug levels of AZD5423 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with four different devices), to healthy subjects</brief_summary>
	<brief_title>A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways</brief_title>
	<detailed_description>A Phase I, Single Centre, Open, Partly Randomised, Crossover Study in Healthy Subjects to Evaluate AZD5423 Absolute Pulmonary Bioavailability when Administered Inhaled via a New Dry Powder Inhaler, Turbuhaler, Spira nebulizer and I-neb AAD system</detailed_description>
	<criteria>Healthy male or women of nonchildbearing potential aged 1845 years inclusive with suitable veins for cannulation or repeated vein puncture Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive and rounding allowed) and weight between 50 and 100 kg (inclusive) Be able to inhale from the inhaler devices used in the study according to given instructions as well as be able to perform spirometry History of any clinically significant disease or disorder Current smokers Any clinically relevant abnormal findings</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Phase I, Healthy male volunteers, pharmacokinetics</keyword>
</DOC>